|
ATAD2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.10279999968144E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.8143000000046E-05 |
| Normal-vs-Stage2 |
1.73690000004889E-06 |
| Normal-vs-Stage3 |
5.96670000074795E-08 |
| Normal-vs-Stage4 |
1.66803999999132E-05 |
| Stage1-vs-Stage2 |
5.605700E-02 |
| Stage1-vs-Stage3 |
2.502400E-02 |
| Stage1-vs-Stage4 |
1.059630E-01 |
| Stage2-vs-Stage3 |
8.017600E-01 |
| Stage2-vs-Stage4 |
8.007200E-01 |
| Stage3-vs-Stage4 |
9.597200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.38930000012938E-07 |
| Normal-vs-AfricanAmerican |
2.049700E-02 |
| Normal-vs-Asian |
5.556900E-04 |
| Caucasian-vs-AfricanAmerican |
4.419600E-01 |
| Caucasian-vs-Asian |
7.094800E-01 |
| AfricanAmerican-vs-Asian |
6.753600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.043400E-04 |
| Normal-vs-Female |
4.7467999975126E-08 |
| Male-vs-Female |
8.548200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.383790E-04 |
| Normal-vs-Age(41-60Yrs) |
1.53410000036658E-07 |
| Normal-vs-Age(61-80Yrs) |
1.14870000000877E-06 |
| Normal-vs-Age(81-100Yrs) |
4.559700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.949900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.486000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.716800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.769000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.502800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.868000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.260200E-03 |
| Classical-VS-Follicular |
7.217600E-03 |
| Classical-VS-Other |
7.368600E-01 |
| Classical-VS-Normal |
5.99039999999995E-05 |
| Tall-VS-Follicular |
4.538400E-01 |
| Tall-VS-Other |
6.334500E-02 |
| Tall-VS-Normal |
1.77480000029817E-07 |
| Follicular-VS-Other |
2.666000E-01 |
| Follicular-VS-Normal |
7.6776000001999E-07 |
| Other-VS-Normal |
2.121200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.06420000034468E-07 |
| Normal-vs-N1 |
4.281600E-03 |
| N0-vs-N1 |
1.461780E-01 |
|
|
